Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.54 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809094 | 0.91 | TACR1 (0.60) | TACR1TACR3CETPJAK2JAK1 | |
| SCHEMBL13756722 | 0.88 | TACR1 (0.57) | TACR1TACR3CETPJAK2JAK1 | |
| SCHEMBL14217465 | 0.86 | TACR1 (0.56) | TACR1TACR3CETPJAK2JAK1 | |
| SCHEMBL14217466 | 0.84 | TACR1 (0.57) | TACR1TACR3 | |
| SCHEMBL13871846 | 0.84 | TACR1 (0.58) | TACR1TACR3CETPJAK2JAK1 | |
| SCHEMBL12809148 | 0.82 | TACR1 (0.53) | TACR1SFRP1TACR3CETP | |
| SCHEMBL14217216 | 0.81 | JAK2 (0.44) | TACR1JAK2JAK1ABHD6DAGLA | |
| SCHEMBL12809200 | 0.81 | TACR1 (0.47) | TACR1 | |
| SCHEMBL3082292 | 0.81 | TACR1 (0.63) | TACR1TACR3 | |
| SCHEMBL12809204 | 0.81 | TACR1 (0.63) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737838-B1 | SUBSTITUTED 4-ALKYL- AND 4-ALKANOYL-PIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-21 | — | — | EP | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | NPSR1, VIP, OPRK1 | TACR1 36/4885SFRP1 4394/4885TACR3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.